vs
Side-by-side financial comparison of FEDERAL AGRICULTURAL MORTGAGE CORP (AGM) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $107.5M, roughly 1.6× FEDERAL AGRICULTURAL MORTGAGE CORP). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 6.1%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 7.1%).
The Federal Agricultural Mortgage Corporation, also known as Farmer Mac, is a stockholder-owned, federally chartered corporation established by the U.S. Congress in 1988 under the Agricultural Credit Act of 1987. It was created to establish a secondary market for agricultural real estate and housing mortgage loans, to increase liquidity and the availability of long-term, stable credit for farmers, ranchers, and rural communities.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
AGM vs ESPR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $107.5M | $168.4M |
| Net Profit | — | — |
| Gross Margin | — | — |
| Operating Margin | 56.3% | 50.6% |
| Net Margin | — | — |
| Revenue YoY | 6.1% | 143.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | $3.69 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $107.5M | $168.4M | ||
| Q3 25 | $104.0M | $87.3M | ||
| Q2 25 | $102.6M | $82.4M | ||
| Q1 25 | $94.3M | $65.0M | ||
| Q4 24 | $101.3M | $69.1M | ||
| Q3 24 | $90.3M | $51.6M | ||
| Q2 24 | $89.9M | $73.8M | ||
| Q1 24 | $93.7M | $137.7M |
| Q4 25 | — | — | ||
| Q3 25 | $55.0M | $-31.3M | ||
| Q2 25 | $54.8M | $-12.7M | ||
| Q1 25 | $49.7M | $-40.5M | ||
| Q4 24 | $56.5M | — | ||
| Q3 24 | $49.8M | $-29.5M | ||
| Q2 24 | $47.1M | $-61.9M | ||
| Q1 24 | $53.7M | $61.0M |
| Q4 25 | 56.3% | 50.6% | ||
| Q3 25 | 64.1% | -11.4% | ||
| Q2 25 | 63.8% | 8.6% | ||
| Q1 25 | 66.9% | -34.0% | ||
| Q4 24 | 67.5% | -6.4% | ||
| Q3 24 | 69.0% | -31.0% | ||
| Q2 24 | 65.9% | 3.5% | ||
| Q1 24 | 72.8% | 52.5% |
| Q4 25 | — | — | ||
| Q3 25 | 52.9% | -35.9% | ||
| Q2 25 | 53.4% | -15.4% | ||
| Q1 25 | 52.6% | -62.2% | ||
| Q4 24 | 55.8% | — | ||
| Q3 24 | 55.2% | -57.2% | ||
| Q2 24 | 52.4% | -83.9% | ||
| Q1 24 | 57.4% | 44.3% |
| Q4 25 | $3.69 | $0.32 | ||
| Q3 25 | $4.44 | $-0.16 | ||
| Q2 25 | $4.48 | $-0.06 | ||
| Q1 25 | $4.01 | $-0.21 | ||
| Q4 24 | $4.62 | $-0.14 | ||
| Q3 24 | $3.86 | $-0.15 | ||
| Q2 24 | $3.68 | $-0.33 | ||
| Q1 24 | $4.28 | $0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $167.9M |
| Total DebtLower is stronger | $30.8B | — |
| Stockholders' EquityBook value | $1.7B | $-302.0M |
| Total Assets | $35.4B | $465.9M |
| Debt / EquityLower = less leverage | 17.93× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $167.9M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $86.1M | ||
| Q1 25 | — | $114.6M | ||
| Q4 24 | — | $144.8M | ||
| Q3 24 | $842.1M | $144.7M | ||
| Q2 24 | $923.0M | $189.3M | ||
| Q1 24 | $745.1M | $226.6M |
| Q4 25 | $30.8B | — | ||
| Q3 25 | $29.2B | — | ||
| Q2 25 | $28.9B | — | ||
| Q1 25 | $28.0B | — | ||
| Q4 24 | $27.5B | — | ||
| Q3 24 | $27.2B | — | ||
| Q2 24 | $26.8B | — | ||
| Q1 24 | $26.8B | — |
| Q4 25 | $1.7B | $-302.0M | ||
| Q3 25 | $1.7B | $-451.4M | ||
| Q2 25 | $1.5B | $-433.5M | ||
| Q1 25 | $1.5B | $-426.2M | ||
| Q4 24 | $1.5B | $-388.7M | ||
| Q3 24 | $1.5B | $-370.2M | ||
| Q2 24 | $1.5B | $-344.2M | ||
| Q1 24 | $1.5B | $-294.3M |
| Q4 25 | $35.4B | $465.9M | ||
| Q3 25 | $33.4B | $364.0M | ||
| Q2 25 | $33.0B | $347.1M | ||
| Q1 25 | $31.8B | $324.0M | ||
| Q4 24 | $31.3B | $343.8M | ||
| Q3 24 | $30.6B | $314.1M | ||
| Q2 24 | $30.2B | $352.3M | ||
| Q1 24 | $29.8B | $373.1M |
| Q4 25 | 17.93× | — | ||
| Q3 25 | 17.31× | — | ||
| Q2 25 | 18.70× | — | ||
| Q1 25 | 18.39× | — | ||
| Q4 24 | 18.48× | — | ||
| Q3 24 | 18.60× | — | ||
| Q2 24 | 17.87× | — | ||
| Q1 24 | 18.11× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $80.1M | $45.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $80.1M | $45.2M | ||
| Q3 25 | $74.2M | $-4.3M | ||
| Q2 25 | $-47.7M | $-31.4M | ||
| Q1 25 | $-49.8M | $-22.6M | ||
| Q4 24 | $612.6M | $-35.0M | ||
| Q3 24 | $-44.4M | $-35.3M | ||
| Q2 24 | $56.1M | $-7.2M | ||
| Q1 24 | $233.3M | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $607.4M | — | ||
| Q3 24 | $-44.4M | $-35.5M | ||
| Q2 24 | $52.6M | $-7.3M | ||
| Q1 24 | $231.7M | $53.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 599.8% | — | ||
| Q3 24 | -49.2% | -68.7% | ||
| Q2 24 | 58.5% | -9.9% | ||
| Q1 24 | 247.3% | 39.0% |
| Q4 25 | 0.0% | 0.0% | ||
| Q3 25 | 0.0% | 0.0% | ||
| Q2 25 | 0.0% | 0.0% | ||
| Q1 25 | 0.0% | 0.0% | ||
| Q4 24 | 5.2% | 0.0% | ||
| Q3 24 | 0.1% | 0.3% | ||
| Q2 24 | 4.0% | 0.1% | ||
| Q1 24 | 1.7% | 0.1% |
| Q4 25 | — | — | ||
| Q3 25 | 1.35× | — | ||
| Q2 25 | -0.87× | — | ||
| Q1 25 | -1.00× | — | ||
| Q4 24 | 10.84× | — | ||
| Q3 24 | -0.89× | — | ||
| Q2 24 | 1.19× | — | ||
| Q1 24 | 4.34× | 0.88× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AGM
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
